VYNE Therapeutics (VYNE) Stock Price, News & Analysis

Company Overview

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation. VTX-002 is in IND-enabling studies for indications such as pulmonary fibrosis and other fibrotic disorders. A second discovery program is focused on a novel mechanism of complement modulation, intended to dampen excessive inflammatory responses in vascular and autoimmune diseases. In addition to these core assets, VYNE maintains a discovery engine aimed at identifying new small molecules with optimized drug-like properties for indications in cardiometabolic and fibrotic pathology.

Since its founding, VYNE Therapeutics has built a leadership team comprised of seasoned executives and scientific founders with prior experience at leading biotechnology and pharmaceutical companies. The company collaborates with academic institutions and contract research organizations to accelerate preclinical and clinical activities. VYNE’s research and development efforts are designed to serve patient populations across North America and Europe, with strategic plans to expand into additional regions through partnerships and licensing agreements.

Key Stats

• Today's Range: $0.62 to $0.66
• 50-Day Range: $0.61 to $0.69
• 52-Week Range: $0.28 to $1.96
• Volume: 18,697 shs
• Average Volume: 255,900 shs
• Market Capitalization: $21.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

VYNE Therapeutics Stock Analysis - MarketRank™

VYNE Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 779th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Reduce

Consensus Rating

VYNE Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

VYNE Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of VYNE Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VYNE Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

VYNE Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.34% of the float of VYNE Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

VYNE Therapeutics has a short interest ratio ("days to cover") of 0.87, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VYNE Therapeutics has recently decreased by 8.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VYNE Therapeutics does not currently pay a dividend.

Dividend Growth

VYNE Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

VYNE Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for VYNE Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.03% of the stock of VYNE Therapeutics is held by insiders.

Percentage Held by Institutions

83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/26/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VYNE
• CIK: 1566044
• Web: vynetherapeutics.com
• Phone: (800) 755-7936
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.48 million
• Net Margins: -4,726.21%
• Pretax Margin: -4,782.82%
• Return on Equity: -70.42%
• Return on Assets: -63.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.86
• Quick Ratio: 20.86

Sales & Book Value

• Annual Sales: $570 thousand
• Price / Sales: 38.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.83 per share
• Price / Book: 0.79

Miscellaneous

• Outstanding Shares: 33,350,000
• Free Float: 32,342,000
• Market Cap: $21.84 million
• Optionable: Not Optionable
• Beta: 2.00